Jincheng Pharm: Morphine Nitrazepam Sodium Injection has obtained a drug registration certificate

According to the announcement from Jincheng Pharm (300233.SZ), its holding subsidiary Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. (referred to as "Jincheng Jinsu") has received the drug registration certificate for Morpholine Nitrazole Sodium Injection issued by the National Medical Products Administration.

The announcement shows that Morpholine Nitrazole is a 5-nitroimidazole antibacterial drug. This product stabilizes its structure by replacing the unstable chloride ion in Ornidazole with a more stable Morpholine ring, resulting in a lower incidence of adverse reactions. This product is suitable for the following infections in adults (≥18 years) caused by sensitive bacteria: 1. Gynecological pelvic inflammatory disease (including endometritis, salpingitis, tubo-ovarian abscess, pelvic peritonitis, etc.) caused by bacteria such as Streptococcus anginosus, Bacteroides fragilis, Veillonella parvula, and Fusobacterium nucleatum; 2. Suppurative appendicitis and gangrenous appendicitis caused by bacteria including Bacteroides (Bacteroides fragilis, Bacteroides ovatus, Bacteroides uniformis, Bacteroides thetaiotaomicron, and Bacteroides species), Clostridium (Clostridium perfringens, Clostridium difficile, Clostridium butyricum, and other Clostridia), Fusobacterium (Fusobacterium necrophorum, Fusobacterium varium), and anaerobic cocci (Streptococcus anginosus, Veillonella parvula); 3. Mixed infections such as pelvic inflammatory disease and appendicitis caused by anaerobic and aerobic bacteria